Study guide
10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
Key Takeaways Explain This Topic AI
Red flags such as rectal bleeding, weight loss, anemia, nocturnal symptoms or new bowel changes after age 50 require referral rather than self-care.
PEG 3350 is the preferred osmotic laxative, and opioid-induced constipation needs a scheduled laxative started with the opioid.
Loperamide is avoided with fever, bloody diarrhea or suspected C. difficile, and oral rehydration is the first priority in acute diarrhea.
Mesalamine (oral plus rectal) is first-line for mild to moderate ulcerative colitis but is not effective in Crohn's disease.
In cirrhosis, ascites is treated with spironolactone and furosemide in a 100:40 ratio, and encephalopathy with lactulose titrated to 2 to 3 soft stools daily.
Last updated: October 2026
Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
Lower gastrointestinal complaints are among the most common self-care questions in community pharmacy. Inflammatory bowel disease and cirrhosis, in turn, are high-risk chronic conditions where drug choice and monitoring prevent hospital admissions. For each problem, decide first whether self-care is appropriate or whether red flags require referral.
Warning
Red flags for referral:
- blood in the stool or black, tarry stools;
- unintended weight loss, or nocturnal symptoms that wake the patient;
- new change in bowel habit after about age 50;
- iron-deficiency anemia;
- a family history of colorectal cancer or IBD;
- fever with diarrhea, or signs of dehydration;
severe abdominal pain.
1. Constipation
Non-drug first: gradually increase fibre (target 25 to 30 g/day) and fluids, add activity, and respond promptly to the urge to defecate. Review constipating drugs: opioids, anticholinergics, calcium channel blockers (verapamil), iron, calcium, and aluminum antacids.
Bulk-forming (psyllium): works over 1 to 3 days. Needs plenty of water. Avoid it in opioid-induced constipation and in bedbound or fluid-restricted patients (risk of impaction).
Osmotic agents: polyethylene glycol 3350 (PEG) is the preferred osmotic for most adults and children. Lactulose works but causes bloating and cramps. Magnesium salts should be avoided in renal impairment.
Stimulants (senna, bisacodyl): act within 6 to 12 hours, and are effective and safe for regular use when needed, including for opioid-induced constipation.
Docusate: little evidence of benefit alone.
Opioid-induced constipation: start a scheduled laxative (PEG and/or senna) with the opioid, because tolerance does not develop to this effect. If laxatives fail, peripherally acting μ-opioid receptor antagonists (methylnaltrexone SC, naloxegol orally) are options. They are contraindicated in bowel obstruction.
2. Acute Diarrhea and Travellers' Diarrhea
Rehydration first: use an oral rehydration solution, especially for children and older adults. Sports drinks and juices are too high in sugar and too low in sodium.
Loperamide: adults take 4 mg after the first loose stool, then 2 mg after each loose stool. Self-care labelling caps the daily dose at 8 mg. Avoid it with fever, bloody stools, suspected C. difficile , or in young children. High doses misused for opioid effects cause QT prolongation and arrhythmias.
Bismuth subsalicylate: useful for travellers' diarrhea. It is a salicylate, so avoid it with warfarin, aspirin allergy, in children recovering from viral illness, and in late pregnancy. It blackens the stool and tongue.
Travellers' diarrhea: most cases resolve without antibiotics. For severe or dysenteric cases, azithromycin is preferred for many destinations because of fluoroquinolone resistance (common in South and Southeast Asia).
Antibiotic-associated diarrhea after recent antibiotics needs C. difficile assessment (section 11.3).
3. Irritable Bowel Syndrome (IBS)
IBS is diagnosed clinically (Rome IV criteria): recurrent abdominal pain related to defecation and to a change in stool frequency or form. It has no red flags.
Foundations: reassurance, soluble fibre (psyllium, not wheat bran), a dietitian-guided low-FODMAP diet , and regular exercise.
Antispasmodics for pain: peppermint oil capsules, hyoscine butylbromide, and pinaverium , a gut-selective calcium channel blocker that is widely used in Canada. Pinaverium is taken with a full glass of water, with food, and sitting upright.
IBS with constipation: PEG, then linaclotide (a guanylate cyclase-C agonist; diarrhea is its main adverse effect).
IBS with diarrhea: loperamide for episodic symptoms, then rifaximin or eluxadoline (avoid eluxadoline after cholecystectomy or with alcohol misuse because of pancreatitis risk).
Neuromodulators: low-dose tricyclics (amitriptyline 10 to 30 mg at bedtime) help pain and diarrhea-predominant symptoms. SSRIs are an alternative when constipation predominates.
4. Inflammatory Bowel Disease (IBD)
Feature Ulcerative colitis (UC) Crohn's disease (CD)
Distribution Continuous, from the rectum upward; mucosal Anywhere from mouth to anus; skip lesions; transmural (fistulas, strictures)
5-ASA (mesalamine) First-line for mild to moderate disease , orally and/or rectally (suppositories for proctitis, enemas for left-sided disease) Not effective for inducing or maintaining remission
Corticosteroids Induce remission in flares (budesonide MMX for mild to moderate; prednisone for more severe). Not for maintenance Ileal budesonide for mild to moderate ileocecal disease; prednisone for more severe flares
Maintenance beyond 5-ASA Thiopurines, biologics (anti-TNF: infliximab, adalimumab; vedolizumab; ustekinumab), JAK inhibitors Thiopurines, methotrexate, biologics
Smoking Ex-smokers are at higher risk of UC, but smoking is never recommended as treatment Smoking worsens CD; cessation is essential
Before starting biologics or JAK inhibitors, screen for tuberculosis and hepatitis B and update vaccinations. Live vaccines are avoided during therapy. Thiopurines need TPMT (and NUDT15) testing and CBC and liver test monitoring.
5. Cirrhosis and Its Complications
Complication Drug management Pharmacist pearls
Ascites Sodium restriction (about 2 g/day) plus spironolactone with furosemide in a 100 mg : 40 mg ratio , titrated together Monitor weight, sodium, potassium and creatinine; avoid NSAIDs, which blunt the diuretic response and harm the kidneys
Hepatic encephalopathy Lactulose , titrated to 2 to 3 soft bowel movements daily ; rifaximin added for recurrence Constipation, GI bleeding, infection, sedatives and hypokalemia precipitate encephalopathy
Varices Non-selective beta-blocker (propranolol, nadolol or carvedilol) for prophylaxis; octreotide and antibiotics for acute bleeding Selective blockers such as metoprolol do not lower portal pressure
Spontaneous bacterial peritonitis prophylaxis Ciprofloxacin or TMP-SMX in selected high-risk patients Review long-term PPIs, which are linked with infection risk
Drug use in cirrhosis:
Acetaminophen remains the preferred analgesic, at reduced daily maximums (many clinicians use about 2 g/day).
NSAIDs are avoided (renal failure, bleeding, diuretic resistance).
Benzodiazepines and opioids can precipitate encephalopathy. If a benzodiazepine is unavoidable, use one cleared by glucuronidation (lorazepam, oxazepam).
The Child-Pugh class guides dose reductions for hepatically cleared drugs.